Therefore, the increased risk of developing aggressive PCa among carriers of the NAT2 (rs1390358 and rs7832071) variant alleles may be linked to decreased detoxification or increased bioactivation of pro-oxidants. This evidence concerns the gene NAT2 and posterior cortical atrophy.